Intramuscular extended‐release naltrexone: current evidence

@article{Gastfriend2011IntramuscularEN,
  title={Intramuscular extended‐release naltrexone: current evidence},
  author={D. Gastfriend},
  journal={Annals of the New York Academy of Sciences},
  year={2011},
  volume={1216}
}
  • D. Gastfriend
  • Published 2011
  • Medicine
  • Annals of the New York Academy of Sciences
Extended‐release naltrexone (XR‐NTX; Vivitrol®), developed to address poor adherence in addictive disorders, is approved for use in alcohol and opioid‐dependence disorders. In alcohol‐dependent adults with ≥4‐day initial abstinence, XR‐NTX increased initial and 6‐month abstinence. An fMRI study found that XR‐NTX attenuated the salience of alcohol visual and olfactory cues in the absence of alcohol, and post hoc analyses demonstrated efficacy even during high cue‐exposure holiday periods. Safety… Expand
62 Citations
Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX)
  • 36
Pharmacological enhancement of naltrexone treatment for opioid dependence: a review
  • 21
  • Highly Influenced
  • PDF
Effectiveness, safety and feasibility of extended‐release naltrexone for opioid dependence: a 9‐month follow‐up to a 3‐month randomized trial
  • 10
  • Highly Influenced
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 148 REFERENCES
Extended-release naltrexone for treatment of alcohol dependence in primary care.
  • 38
Long-acting injectable naltrexone for the treatment of alcohol dependence
  • 20
Utilization patterns of extended-release naltrexone for alcohol dependence.
  • 5
Naltrexone in the treatment of alcohol dependence.
  • 473
  • PDF
...
1
2
3
4
5
...